Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + S-1 neoadjuvant chemoradiotherapy for borderline resectable pancreatic cancer
jRCTs021180045Phase 2Completed
- Sponsor
- Study Group of Preoperative Therapy for Pancreatic Cancer
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and tegafur in pancreatic cancer (PC), sponsored by Study Group of Preoperative Therapy for Pancreatic Cancer. Primary endpoints: Maximum tolerated dose and Recommended dose. Started Mar 2019; status: completed.
02
Drugs
gemcitabinetegafur
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCTs021180045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021180045.